Small molecule binding sites on the Ras:SOS complex can be exploited for inhibition of Ras activation.
暂无分享,去创建一个
Malcolm Anderson | Jason G Kettle | Alexander L Breeze | M Raymond V Finlay | A. Breeze | C. Chresta | J. Tucker | Malcolm A. Anderson | A. Tucker | R. Overman | M. Finlay | Paula Perkins | G. Wrigley | Paul F. Faulder | Julie A Tucker | Ross Overman | K. Embrey | J. Tart | T. Nowak | J. Kettle | Kevin Blades | J. Winter | C. Brassington | Gary Fairley | Julie | Kevin Embrey | Loredana Spadola | G. Fairley | S. Patel | L. Spadola | Paula Perkins | Jon J G Winter | Kevin Blades | Claire Brassington | Christine Chresta | Paul Faulder | Thorsten Nowak | S Joe Patel | Jonathan Tart | Gail Wrigley | P. Faulder
[1] P. Emsley,et al. Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.
[2] Paramjit S Arora,et al. Contemporary strategies for the stabilization of peptides in the alpha-helical conformation. , 2008, Current opinion in chemical biology.
[3] T. Earnest,et al. Using fragment cocktail crystallography to assist inhibitor design of Trypanosoma brucei nucleoside 2-deoxyribosyltransferase. , 2006, Journal of medicinal chemistry.
[4] Robert A. Weinberg,et al. Ras oncogenes: split personalities , 2008, Nature Reviews Molecular Cell Biology.
[5] Clemens Vonrhein,et al. Exploiting structure similarity in refinement: automated NCS and target-structure restraints in BUSTER , 2012, Acta crystallographica. Section D, Biological crystallography.
[6] M. Potashman,et al. Covalent modifiers: an orthogonal approach to drug design. , 2009, Journal of medicinal chemistry.
[7] A. Kalgutkar,et al. Drug discovery for a new generation of covalent drugs , 2012, Expert opinion on drug discovery.
[8] J. Cherfils,et al. Structural snapshots of the mechanism and inhibition of a guanine nucleotide exchange factor , 2003, Nature.
[9] Clemens Vonrhein,et al. Data processing and analysis with the autoPROC toolbox , 2011, Acta crystallographica. Section D, Biological crystallography.
[10] J. Andrew Grant,et al. Small Molecule Shape-Fingerprints , 2005, J. Chem. Inf. Model..
[11] Robert Mah,et al. Drug discovery considerations in the development of covalent inhibitors. , 2014, Bioorganic & medicinal chemistry letters.
[12] M. Congreve,et al. A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.
[13] Andre Hoelz,et al. Structural Evidence for Feedback Activation by Ras·GTP of the Ras-Specific Nucleotide Exchange Factor SOS , 2003, Cell.
[14] C. Der,et al. Specificity and Mechanism of Action of EHT 1864, a Novel Small Molecule Inhibitor of Rac Family Small GTPases* , 2007, Journal of Biological Chemistry.
[15] J. Acker,et al. Brefeldin A acts to stabilize an abortive ARF-GDP-Sec7 domain protein complex: involvement of specific residues of the Sec7 domain. , 1999, Molecular cell.
[16] Qi Sun,et al. Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. , 2012, Angewandte Chemie.
[17] Randy J. Read,et al. Overview of the CCP4 suite and current developments , 2011, Acta crystallographica. Section D, Biological crystallography.
[18] Fabrizio Giordanetto,et al. Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties? , 2014, Journal of medicinal chemistry.
[19] Philipp M. Cromm,et al. Small-molecule modulation of Ras signaling. , 2014, Nature chemical biology.
[20] Stefan G. Kathman,et al. A Fragment-Based Method to Discover Irreversible Covalent Inhibitors of Cysteine Proteases , 2014, Journal of medicinal chemistry.
[21] M. Broggini,et al. RAS/RAF/MEK inhibitors in oncology. , 2012, Current medicinal chemistry.
[22] Rutger H A Folmer,et al. Fragment screening to predict druggability (ligandability) and lead discovery success. , 2011, Drug discovery today.
[23] Taebo Sim,et al. Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor. , 2014, Angewandte Chemie.
[24] I. Mellman,et al. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity , 2012, Proceedings of the National Academy of Sciences.
[25] E. Olejniczak,et al. Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange , 2014, Proceedings of the National Academy of Sciences.
[26] Jon Winter,et al. Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generation. , 2012, Journal of medicinal chemistry.
[27] B. Cravatt,et al. Strategies for discovering and derisking covalent, irreversible enzyme inhibitors. , 2010, Future medicinal chemistry.
[28] Matthew Grist,et al. Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR). , 2013, Journal of medicinal chemistry.
[29] Kevan M. Shokat,et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions , 2013, Nature.
[30] P. Macfaul,et al. A simple in vitro assay for assessing the reactivity of nitrile containing compounds. , 2009, Bioorganic & medicinal chemistry letters.
[31] John Kuriyan,et al. The structural basis of the activation of Ras by Sos , 1998, Nature.
[32] P. Arora,et al. Contemporary Strategies for the Stabilization of Peptides in the α-Helical Conformation , 2009 .
[33] K Wüthrich,et al. Single Transition-to-single Transition Polarization Transfer (ST2-PT) in [15N,1H]-TROSY , 1998, Journal of biomolecular NMR.